NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

10374	Companies
216189	Keywords
145888	Articles
114464	Press releases

Home
Companies
NanoViricides, Inc.

BRIEF

published on 09/11/2025 at 14:35, 7 months 29 days ago

NanoViricides to Present at LSX World Congress in Boston

NanoViricides NV-387 Clinical Trials Antiviral Drug LSX Congress
PRESS RELEASE

published on 09/11/2025 at 14:30, 7 months 29 days ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
NanoViricides, Inc. announces participation in LSX World Congress 2025 to present revolutionary broad-spectrum antiviral drug NV-387 and potential impact on viral infections

NanoViricides NV-387 Antiviral Drug Viral Infections LSX World Congress
BRIEF

published on 09/09/2025 at 14:35, 8 months 1 day ago

NanoViricides présentera un médicament antiviral révolutionnaire au congrès LSX

NanoViricides NV-387 Essai Clinique Médicaments Antiviraux Congrès LSX
BRIEF

published on 09/09/2025 at 14:35, 8 months 1 day ago

NanoViricides to Showcase Revolutionary Antiviral Drug at LSX Congress

NanoViricides NV-387 Antiviral Drugs Clinical Trial LSX Congress
PRESS RELEASE

published on 09/09/2025 at 14:30, 8 months 1 day ago

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
NanoViricides, Inc. to showcase revolutionary antiviral drug NV-387 at LSX World Congress 2025 in Boston. Update on drug pipeline and platform technologies by Dr. Diwan

NanoViricides NV-387 Antiviral Drug LSX World Congress Dr. Diwan
BRIEF

published on 08/18/2025 at 14:35, 8 months 23 days ago

NanoViricides annonce l'essai clinique prometteur du médicament antiviral NV-387

NV-387 Essais Cliniques Inflammation Anti-cancer Médicament Antiviral
BRIEF

published on 08/18/2025 at 14:35, 8 months 23 days ago

NanoViricides Reports Promising Antiviral Drug NV-387 in Clinical Trials

NV-387 Clinical Trials Antiviral Drug Inflammation Anti-cancer
PRESS RELEASE

published on 08/18/2025 at 14:30, 8 months 23 days ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
NanoViricides, Inc. reports NV-387 antiviral drug could reduce metastatic cancer resurgence caused by viral infections. NV-387 completed Phase I trial, advancing to Phase II

NV-387 NanoViricides Inc. Antiviral Drug Viral Infections Metastatic Cancer
BRIEF

published on 07/30/2025 at 14:35, 9 months 11 days ago

NanoViricides présente le NV-387 comme une solution clé contre la rougeole face à l'augmentation des cas

Désignation De Médicament Orphelin Médicament NV-387 Augmentation De La Rougeole Vaccination Mondiale Risque Pour La Santé Publique
BRIEF

published on 07/30/2025 at 14:35, 9 months 11 days ago

NanoViricides Highlights NV-387 as Key Measles Solution Amid Rising Cases

Orphan Drug Designation NV-387 Drug Measles Increase Global Vaccination Public Health Risk

Accesswire

Published on 05/09/2026 at 01:55, 1 day 21 hours ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 1 day 22 hours ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 1 day 22 hours ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 23 hours ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 2 days ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/10/2026 at 16:05, 7 hours 46 minutes ago

RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 9 hours 51 minutes ago

MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 12 hours 6 minutes ago

Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 1 day 4 hours ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 2 days 3 hours ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations

Les Echos

Published on 05/07/2026 at 19:15, 3 days 4 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days 4 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 days 4 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 days 4 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 days 4 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE